FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W18765727> ?p ?o ?g. }

• W18765727 endingPage "85" @default.
• W18765727 startingPage "S179" @default.
• W18765727 abstract "Recent studies report that the radiolabelled synthetic somatostatin analogue, [111In-DTPA-DPhe1]octreotide, is useful for imaging carcinoid tumours and pancreatic endocrine tumours. At present, it is unclear whether this method is superior to conventional imaging studies (computed tomography, magnetic resonance imaging, ultrasound, angiography) and what its role should be, if any, in the management of these patients. The aim of this paper is to review five recent studies performed at the National Institutes of Health in patients with Zollinger-Ellison syndrome to define the role of somatostatin receptor scintigraphy. Patients were from a tertiary referral centre, all had Zollinger-Ellison syndrome. In Study n. 1: the sensitivity of somatostatin receptor scintigraphy was assessed compared to conventional studies in 80 patients. Study n. 2: the effect of somatostatin receptor scintigraphy on management was determined in 122 patients. Study n. 3: ability of somatostatin receptor scintigraphy and other conventional methods to distinguish small hepatic metastases (< 2 cm) from hepatic haemangiomas was assessed in 29 patients. Study n. 4: somatostatin receptor scintigraphy, magnetic resonance imaging and bone scanning were compared in 115 consecutive patients to detect bone metastases. Study n. 5: ability of somatostatin receptor scintigraphy to detect gastrinomas found at surgery in 35 patients and its effect on cure rate and determinants of detection of gastrinomas by somatostatin receptor scintigraphy were analysed. Briefly, results showed: Study n. 1: somatostatin receptor scintigraphy is the most sensitive modality for detection of primary or metastatic gastrinomas; Study n. 2: somatostatin receptor scintigraphy changes management in 47% of cases; Study n. 3: somatostatin receptor scintigraphy is the only method to distinguish small liver metastases from small haemangiomas; Study n. 4: somatostatin receptor scintigraphy and magnetic resonance imaging have higher sensitivity and predictive values for bone metastases than bone scanning; Study n. 5: somatostatin receptor scintigraphy misses 33% of gastrinomas found at surgery, primarily small duodenal tumours. Size is the important factor. The use of somatostatin receptor scintigraphy does not increase cure rate. In conclusion, Somatostatin receptor scintigraphy is now the imaging method of choice in patients with Zollinger-Ellison syndrome for preoperative primary tumour localization, detection of bone or liver metastases, and to distinguish small liver metastases from small hepatic haemangiomas. Its specificity appears to be high but has been poorly studied as has the use of it in combination with endoscopic ultrasound. Studies by others suggest these recommendations will apply to carcinoid tumours and other pancreatic endocrine tumours except insulinomas." @default.
• W18765727 created "2016-06-24" @default.
• W18765727 creator A5005161415 @default.
• W18765727 creator A5040798984 @default.
• W18765727 date "1999-10-01" @default.
• W18765727 modified "2023-09-24" @default.
• W18765727 title "Somatostatin receptor scintigraphy in gastrinomas." @default.
• W18765727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10604126" @default.
• W18765727 hasPublicationYear "1999" @default.
• W18765727 type Work @default.
• W18765727 sameAs 18765727 @default.
• W18765727 citedByCount "6" @default.
• W18765727 countsByYear W187657272014 @default.
• W18765727 countsByYear W187657272017 @default.
• W18765727 crossrefType "journal-article" @default.
• W18765727 hasAuthorship W18765727A5005161415 @default.
• W18765727 hasAuthorship W18765727A5040798984 @default.
• W18765727 hasConcept C126322002 @default.
• W18765727 hasConcept C126838900 @default.
• W18765727 hasConcept C143409427 @default.
• W18765727 hasConcept C2776297358 @default.
• W18765727 hasConcept C2776986829 @default.
• W18765727 hasConcept C2779066768 @default.
• W18765727 hasConcept C2779902710 @default.
• W18765727 hasConcept C2781025020 @default.
• W18765727 hasConcept C2781283050 @default.
• W18765727 hasConcept C2989005 @default.
• W18765727 hasConcept C49039625 @default.
• W18765727 hasConcept C71924100 @default.
• W18765727 hasConcept C80115893 @default.
• W18765727 hasConceptScore W18765727C126322002 @default.
• W18765727 hasConceptScore W18765727C126838900 @default.
• W18765727 hasConceptScore W18765727C143409427 @default.
• W18765727 hasConceptScore W18765727C2776297358 @default.
• W18765727 hasConceptScore W18765727C2776986829 @default.
• W18765727 hasConceptScore W18765727C2779066768 @default.
• W18765727 hasConceptScore W18765727C2779902710 @default.
• W18765727 hasConceptScore W18765727C2781025020 @default.
• W18765727 hasConceptScore W18765727C2781283050 @default.
• W18765727 hasConceptScore W18765727C2989005 @default.
• W18765727 hasConceptScore W18765727C49039625 @default.
• W18765727 hasConceptScore W18765727C71924100 @default.
• W18765727 hasConceptScore W18765727C80115893 @default.
• W18765727 hasLocation W187657271 @default.
• W18765727 hasOpenAccess W18765727 @default.
• W18765727 hasPrimaryLocation W187657271 @default.
• W18765727 hasRelatedWork W1542976343 @default.
• W18765727 hasRelatedWork W1986723218 @default.
• W18765727 hasRelatedWork W2028767994 @default.
• W18765727 hasRelatedWork W2033480787 @default.
• W18765727 hasRelatedWork W2038672008 @default.
• W18765727 hasRelatedWork W2053817649 @default.
• W18765727 hasRelatedWork W2115479831 @default.
• W18765727 hasRelatedWork W2116858815 @default.
• W18765727 hasRelatedWork W2337852823 @default.
• W18765727 hasRelatedWork W2744424417 @default.
• W18765727 hasVolume "31 Suppl 2" @default.
• W18765727 isParatext "false" @default.
• W18765727 isRetracted "false" @default.
• W18765727 magId "18765727" @default.
• W18765727 workType "article" @default.